FDA commissioner hints at cardio-related label expansion for Wegovy, full approval for Lilly’s new Alzheimer’s drug

WASH­ING­TON — FDA Com­mis­sion­er Rob Califf took the podi­um Wednes­day af­ter­noon at the Na­tion­al Press Club, of­fer­ing up more warn­ings about mis­in­for­ma­tion lead­ing to de­clin­ing vac­cine up­take, and his usu­al quips about de­clin­ing life ex­pectan­cy.

But he al­so hint­ed at two up­com­ing mile­stones: an ex­pand­ed la­bel for No­vo Nordisk’s GLP-1 ag­o­nist We­govy (semaglu­tide) that fea­tures its car­dio­vas­cu­lar ben­e­fits, and a full ap­proval for Eli Lil­ly’s new Alzheimer’s drug do­nanemab, which will like­ly be a block­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.